US biotech company Neurogene has announced that a new 'product candidate' for the treatment of Rett syndrome has been added to its development pipeline.
GHO Capital Partners, a specialist investor in global healthcare, has invested in RoslinCT, a University of Edinburgh spinout company focused on advanced cell therapies.
An £8.7 million, five-year research collaboration led by the
University of Edinburgh and FUJIFILM Diosynth Biotechnologies UK (FDB)
will develop more cost-effective ways to make modern antibody-based
medicines.
What’s your next challenge? Spin in, spin out or start up?
